Compare · AKBA vs KDNY
AKBA vs KDNY
Side-by-side comparison of Akebia Therapeutics Inc. (AKBA) and Chinook Therapeutics Inc. (KDNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKBA and KDNY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- KDNY is the larger of the two at $670.6M, about 1.9x AKBA ($359.5M).
- AKBA has hit the wire 11 times in the past 4 weeks while KDNY has been quiet.
- AKBA has more recent analyst coverage (11 ratings vs 5 for KDNY).
- Company
- Akebia Therapeutics Inc.
- Chinook Therapeutics Inc.
- Price
- -
- -
- Market cap
- $359.5M
- $670.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 11
- 0
- Recent ratings
- 11
- 5
Akebia Therapeutics Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Chinook Therapeutics Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.
Latest AKBA
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SVP, CFO, CBO & Treasurer Ostrowski Erik sold $62,181 worth of shares (56,019 units at $1.11), decreasing direct ownership by 8% to 616,616 units (SEC Form 4) to satisfy withholding tax
- Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
- Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 27% to 169,081 units (SEC Form 4)
- Director Smith Cynthia was granted 35,700 shares, increasing direct ownership by 22% to 196,633 units (SEC Form 4)
- Director Rogers Michael W was granted 35,700 shares, increasing direct ownership by 22% to 197,429 units (SEC Form 4)
- Director Frieson Ron was granted 35,700 shares, increasing direct ownership by 28% to 165,200 units (SEC Form 4)
- Akebia Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 33% to 145,100 units (SEC Form 4)
Latest KDNY
- SEC Form SC 13D/A filed by Chinook Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Chinook Therapeutics Inc.
- SEC Form EFFECT filed by Chinook Therapeutics Inc.
- SEC Form SC 13D filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.